XML 114 R100.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 12, 2023
USD ($)
Aug. 02, 2022
USD ($)
$ / shares
shares
May 02, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
test
$ / shares
Jun. 23, 2021
USD ($)
Apr. 14, 2021
USD ($)
$ / shares
shares
Jan. 11, 2021
USD ($)
shares
Jan. 05, 2021
USD ($)
$ / shares
shares
May 31, 2022
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Apr. 30, 2021
USD ($)
shares
Jan. 31, 2021
USD ($)
shares
Mar. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
$ / shares
Aug. 23, 2023
USD ($)
May 01, 2022
USD ($)
May 03, 2021
Acquisition                                        
Shares issued, price per share (in usd per share) | $ / shares                           $ 73.98            
Contingent consideration, liability       $ 359,021,000           $ 359,021,000       $ 288,657,000 $ 306,927,000 $ 359,021,000 $ 359,021,000      
Stock-based compensation expense                           231,312,000 206,823,000   339,226,000      
Remeasurement of contingent consideration liabilities                           (18,044,000) (56,617,000)   6,360,000      
Stock-based compensation                           231,312,000 206,823,000   253,063,000      
Stock issued during period, value, acquisitions                           1,675,000 14,792,000   1,355,170,000      
Consideration transferred, net of cash acquired                           52,413,000 14,686,000   499,730,000      
Noncash or part noncash divestiture, amount of consideration received, fair value | $ / shares   $ 6.70                                    
Finite-lived Intangible assets, net                           640,396,000 $ 706,240,000          
Period of lab testing services   24 months                                    
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]                             Other operating income (loss)          
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Contract with Customer, Receivable, after Allowance for Credit Loss                           31,600,000            
Contract with Customer, Asset, after Allowance for Credit Loss                           41,700,000 $ 0          
TARDIS Technology                                        
Acquisition                                        
Asset acquisition, consideration transferred             $ 52,300,000                          
Payments to acquire productive assets             $ 25,000,000                          
Payments to acquire productive assets (in shares) | shares             191,336                          
Stock issued to acquire productive assets, value             $ 27,300,000                          
Payments contingent on milestones             $ 45,000,000                          
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Oncotype DX Genomic Prostate Score Test                                        
Acquisition                                        
Total consideration   $ 29,631,000                                    
Noncash or part noncash divestiture, amount of consideration received, shares | shares   691,171                                    
Disposal group, contingent consideration arrangements, range of outcomes, value, high   $ 70,000,000                               $ 82,500,000    
Finite-lived Intangible assets, net   $ 42,900,000                                    
Disposal group, not discontinued operation, gain (loss) on disposal                             13,200,000          
Disposal Group, Contingent Consideration Arrangements, Gain (Loss)                           73,300,000            
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Disposal Group, Contingent Consideration Arrangements, Gain (Loss)                           73,300,000            
Thrive                                        
Acquisition                                        
Investment owned, fair value               $ 12,500,000                        
Business combination, equity interest in acquiree, remeasurement gain                         $ 7,600,000              
Remeasurement of contingent consideration liabilities                                 7,200,000      
Customer relationships                                        
Acquisition                                        
Finite-lived Intangible assets, net                           $ 3,111,000 $ 3,556,000          
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Weighted Average Remaining Life (Years)                           7 years 8 years          
Trade name                                        
Acquisition                                        
Finite-lived Intangible assets, net                           $ 76,097,000 $ 83,347,000          
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Weighted Average Remaining Life (Years)                           11 years 7 months 6 days 12 years 6 months          
General and administrative                                        
Acquisition                                        
Stock-based compensation expense                           $ 103,757,000 $ 91,212,000   $ 216,952,000      
Investment Income | Thrive                                        
Acquisition                                        
Business combination, equity interest in acquiree, remeasurement gain                         30,500,000              
OmicEra                                        
Acquisition                                        
Total purchase price     $ 19,408,000                                  
Equity issued to acquire business (in shares) | shares                 265,186                      
Shares issued, price per share (in usd per share) | $ / shares     $ 55.78                                  
Contingent payment obligations     $ 6,000,000                                  
Contingent consideration, liability     4,600,000                                  
Developed technology     $ 10,000,000                                  
Weighted-average remaining useful life of finite-lived intangible asset (in years)     16 years                                  
Fair value of stock issued in acquisition                                     $ 14,792,000  
Common stock issued     $ 14,792,000                                  
OmicEra Diagnostics Acquisition                                        
Acquisition                                        
Equity issued to acquire business (in shares) | shares                 265,186                      
PreventionGenetics                                        
Acquisition                                        
Total purchase price       $ 185,381,000                                
Equity issued to acquire business (in shares) | shares                   1,070,410                    
Shares issued, price per share (in usd per share) | $ / shares       $ 78.71           $ 78.71           $ 78.71 $ 78.71      
Number of tests provided | test       5,000                                
Cash       $ 101,129,000                                
Business combination, cash withheld                             $ 15,300,000          
Fair value of stock issued in acquisition       84,252,000           $ 84,252,000           $ 84,252,000 $ 84,252,000      
Common stock issued       84,252,000                                
PreventionGenetics | Payment 1                                        
Acquisition                                        
Cash       $ 85,800,000                                
Ashion Analytics                                        
Acquisition                                        
Total purchase price           $ 109,999,000                            
Equity issued to acquire business (in shares) | shares           125,444         125,444                  
Shares issued, price per share (in usd per share) | $ / shares           $ 129.33                            
Cash           $ 74,775,000                            
Fair value of stock issued in acquisition                     $ 16,224,000                  
Common stock issued           16,224,000                            
Ashion Analytics | Commercial Launch Milestone                                        
Acquisition                                        
Contingent consideration, liability           19,000,000                            
Additional cash consideration to be paid           20,000,000                            
Ashion Analytics | MRD Product Revenue Milestone                                        
Acquisition                                        
Contingent consideration, liability           30,000,000                            
Revenue milestone           $ 500,000,000                            
Thrive                                        
Acquisition                                        
Total purchase price               $ 2,187,054,000                        
Equity issued to acquire business (in shares) | shares               9,323,266       9,323,266                
Shares issued, price per share (in usd per share) | $ / shares               $ 127.79                        
Contingent consideration, liability               $ 450,000,000                        
Cash               584,996,000                        
Fair value of stock issued in acquisition               1,190,000,000       $ 1,191,420,000                
Common stock issued               1,175,431,000                        
Payments to acquire businesses and accelerated vesting of awards               590,200,000                        
Stock-based compensation expense               166,000,000                        
Compensation consideration assumed               197,000,000                        
Compensation consideration assumed and allocated to consideration transferred               52,200,000                        
Compensation consideration assumed and deemed compensatory               144,800,000                        
Non-cash stock-based compensation expense               65,000,000                        
Share based compensation, costs not yet recognized               $ 79,800,000                        
Share conversion ratio               0.06216                        
Business combination, pro forma loss                               $ 255,000,000        
Acquisition related costs                         10,300,000       10,300,000      
Stock-based compensation                                 19,000,000      
Additional benefit charges                                 3,900,000      
Thrive | Employees with Qualifying Termination Events                                        
Acquisition                                        
Non-cash stock-based compensation expense                         13,500,000              
Thrive | Fair Value                                        
Acquisition                                        
Contingent consideration, liability               $ 352,000,000                        
Thrive | FDA Approval                                        
Acquisition                                        
Contingent consideration, liability               150,000,000                        
Thrive | CSM Coverage                                        
Acquisition                                        
Contingent consideration, liability               300,000,000                        
Thrive | Allocated to Consideration Transferred | Fair Value                                        
Acquisition                                        
Contingent consideration, liability               331,300,000                        
Thrive | Allocated to Previous Ownership Interest | Fair Value                                        
Acquisition                                        
Contingent consideration, liability               6,400,000                        
Thrive | Allocated to Compensation | Fair Value                                        
Acquisition                                        
Contingent consideration, liability               14,300,000                        
Thrive | Compensation Expense                                        
Acquisition                                        
Contingent payment obligations               18,200,000                        
Thrive | General and administrative                                        
Acquisition                                        
Incremental share based compensation expense               16,000,000                        
Stock-based compensation expense               $ 5,200,000                        
Non-cash stock-based compensation expense                         $ 86,200,000       $ 86,200,000      
PFS Genomics                                        
Acquisition                                        
Total purchase price         $ 33,600,000                              
Percent of equity acquired         10.00%                             90.00%
Equity interest in acquiree after subsequent acquisition         100.00%                              
Resolution Bioscience                                        
Acquisition                                        
Total purchase price $ 54,202,000                                      
Developed technology 26,000,000                                      
Cash 52,527,000                                      
Common stock issued $ 1,675,000                                      
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method 4.6 million                                      
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory $ 2,900,000                                      
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method 4.6 million                                      
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory $ 2,900,000                                      
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method 4.6 million